november 2, 2017
.
.jeffrey krasner is president of emerging biocommunications, which consults to early- and mid-stage life science companies.
.u.s.
.
.
.
.
yet these drugs are not a "home run," says elizabeth loder, md, a professor of neurology at harvard medical school and chief of the division of headache at brigham & women's hospital.
.
.